May, 3, 2010 – NexBio, Inc. announced the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease. Patients with pre-existing pulmonary illnesses such as these are at high risk for complications of influenza and have limited antiviral drug options, due both to side effects and possible drug resistance. More information about the study may be found at www.clinicaltrials.gov.
DAS181 is a novel broad-spectrum, host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness (ILI) and has shown preclinical activity against numerous strains of influenza and parainfluenza virus. DAS181 blocks entry of these viruses into cells of the respiratory tract. In November 2009, NexBio announced data at the annual American College of Allergy, Asthma, and Immunology meeting demonstrating anti-asthma activity of DAS181 in multiple animal models of asthma... [PDF] NexBio's Press Release -
Blog Archive
-
▼
2010
(63)
-
▼
May
(9)
- Breathe Technologies Secures $23 Million in Series...
- Funxional Therapeutics : ...10 million Euros... to...
- Cardiocom : Telehealth Platform with New Pulse Oxi...
- Cytokinetics : Non-Clinical Data from Its Smooth M...
- Galapagos and Roche : COPD alliance
- Cellceutix : Important New Data on Kevetrin(TM) i...
- Nabriva Therapeutics : successful Phase I clinical...
- NexBio : Clinical Trial of DAS181 (Fludase®*) in A...
- Mylan Pharmaceuticals : Approval for Generic Versi...
-
▼
May
(9)